Introduction: Although a large recent trial had
influence of gender differences on such outcomes is not known. Thus, we aimed to assess the impact of gender on such outcomes in the patients with type 2 diabetes mellitus receiving SGLT-2 inhibitors. Methods: A search of electronic databases was conducted for all randomized trials comparing SGLT-2 inhibitors with placebo in patients with diabetes mellitus. Primary outcomes were all-cause mortality and cardiovascular mortality. Random effects meta-regression was conducted using the percentage of women included in the SGLT-2 inhibitor arm of each trial with a P value of \0. 1 [1] . On subgroup analysis by gender, the risk of all-cause mortality, and cardiovascular mortality appeared to be reduced only in men [1] . In addition, some studies had suggested possible gender differences in the risk of cardiovascular events in patients with type 2 diabetes [2, 3] . Therefore, we aimed to explore the impact of gender on the cardiovascular benefits observed with SGLT-2 inhibitors in type 2 diabetes.
METHODS
A detailed explanation of the methods was discussed in a prior publication [4] inhibitor arm was higher. Although EMPA-REG OUTCOME trial showed a significant reduction in adverse cardiovascular outcomes with empagliflozin, approximately 70% of the patients were men [1] . A subgroup analysis of EMPA-REG OUTCOME trial suggested that there might be possible gender differences: hazard ratio (HR) 0.62, 95% CI 0.50-0.77 in men, versus HR 0.91, 95% CI 0.63-1.32 in women for all-cause mortality [5] . These speculations are further supported by our analysis. Experimental animal studies had suggested that the expression of SGLT-2 co-transported protein and SGLT-2 inhibitors metabolism are different in males compared with females [6] ; however, these findings were not supported in human studies [7] . Some studies have shown that cardiovascular morbidity and mortality are more pronounced in diabetic women compared with men, despite adherence to the guideline recommended therapies, as a result of the higher risk factor 
CONCLUSION
In conclusion, gender might influence the cardiovascular benefits observed with SGLT-2 inhibitors in patients with type 2 DM. Future randomized trials are required to confirm these findings. authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. 
